江来 赁可 杨进源 姜毅 杨浩 王岐本.人重组内皮抑素辅助化疗对食管癌疗效分析[J].,2015,15(29):5705-5707 |
人重组内皮抑素辅助化疗对食管癌疗效分析 |
Analysis on the Effect of Endorstar Adjuvant Chemotherapy on EsophagealCarcinoma |
|
DOI: |
中文关键词: 人重组内皮抑素 食管癌 化疗 |
英文关键词: Recombinant human endostatin Esophageal cancer Chemotherapy |
基金项目:四川省教育厅青年基金项目(07ZB286) |
|
摘要点击次数: 737 |
全文下载次数: 0 |
中文摘要: |
目的:评估人重组内皮抑素(endostar,ES)辅助化疗药物治疗食管癌的临床效果。方法:研究共入组128 例食管癌患者,根据
化疗方案将患者分为试验组与对照组,试验组患者(n=60)进行5 个疗程ES 联合化疗,每个化疗疗程持续3 周,静脉注射ES 15
mg/d。对照组患者(n=68)未使用ES 化疗。化疗2 个疗程后,手术切除肿瘤,分析肿瘤对化疗的反应。检测血管内皮生长因子
(vascular endothelial growth factor ,VEGF)和血小板- 内皮细胞粘附分子(Platelet endothelial cell adhesion molecule-1,CD31)的表
达。结果:同治疗前比较,化疗明显促进了食管癌肿瘤组织中的VEGF的表达和组织中血管的再生。两组相比,试验组患者的生存
率明显提高,转移率明显降低,通过重组内皮抑素治疗显著抑制了化疗引起的VEGF 的表达和微血管的生成。结论:联合重组内
皮抑素化疗能够显著改善食管癌患者的临床结局。 |
英文摘要: |
Objective:To evaluate the clinical effect of Endostar (ES, recombinant human endostatin) in the treatment of
esophageal carcinoma.Methods:This study included 128 cases of esophageal cancer patients. They were divided into two groups. Patients
in test group were treated with ES combined with chemotherapy for 5 courses (n=60), and each course of chemotherapy lasted for 3
weeks, by intravenous injection ES for 15mg/day. Patients in control group were treated without ES (n=68). After two courses of
chemotherapy, the tumor was resected and its response to chemotherapy was analyzed. Immunohistochemical method was used to analyze
the expression of VEGF and CD31 in pathological slices.Results:Compared with before treatment, chemotherapy can significantly
promote the angiogenesis and VEGF expression in the tumor tissue of esophageal cancer. In comparison between the two groups, the survival
rate of test group was obviously improved, and the transfer rate was significantly reduced. The ES treatment significantly inhibited
the expression of chemotherapy-induced VEGF and microvascular.Conclusion:Combined chemotherapy with ES can significantly improve
the clinical outcome of patients with carcinoma of esophagus. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |